investigators presented noteworthy findings on an innovative gene therapy for sickle cell disease, CAR T-cell therapy in high-risk large B cell lymphoma, and research in stem cell transplantation.
In this "in-between-isode" of MedPage Today's Podcast series, Anamnesis, one of our reporters discusses some of these data.
Host: Hello, and thanks for joining us for the latest in-between-isode of Anamnesis.
ASH 2020 was a virtual event this year due to COVID-19, but
MedPage Today's reporter, Ian Ingram, followed all the major developments from the conference.
Ingram: One notable study at this year's ASH meeting found that older, high-risk patients with myelodysplastic syndromes, or MDS, lived significantly longer when they underwent allogeneic hematopoietic stem-cell transplantation.